Vol. 20/No. 12

Radiopharmaceuticals have been integrated into the treatment paradigm for patients with neuroendocrine tumors, yet there are nuances in the clinical scenarios in which they are most effective.

The identification of appropriate biomarkers for evaluating responses to therapy would be beneficial across all stages of ovarian cancer, from early to advanced.

Growing awareness is prompting a revolution in vigilance and attention to detail that has significance both for the quality of care and financial health of practices.

Alexander E. Perl, MD, discusses gilteritinib’s place in the acute myeloid leukemia landscape and its potential future in the frontline setting.

Anlotinib, a novel tyrosine kinase inhibitor capable of mounting a multipronged attack against oncogenic processes, is being tested in rare soft tissue sarcoma subtypes where patients have limited therapeutic options.

During a recent OncLive Peer Exchange discussion, a trio of immune thrombocytopenia specialists review clinical trial data that led to approval of the second-line agents, talk about efforts to refine first-line treatment, and discuss how they approach therapy selection for refractory patients. Finally, they highlight emerging therapies for ITP and the need to expand the pipeline.

Investigators at the University of Wisconsin American Family Children’s Hospital are developing a new approach to treating patients with neuroblastoma that has the potential to improve outcomes for patients whose disease has not responded to conventional therapy.

Named the medical invention of the Year by TIME magazine at the turn of the millennium, positron emission tomography/computed tomography has changed the landscape of cancer diagnosis, facilitating earlier detection and more accurate staging of a range of tumor types.

The search for effective alternatives to radical cystectomy (RC) in patients with bladder cancer has lasted more than 3 decades. Progress has been slow, but investigators have proved that a combination of radiation, chemotherapy, and maximal transurethral resection of the bladder tumor works as well as RC in carefully selected patients.

Having a late-stage treatment for pancreatic cancer that avoids many of the adverse events associated with chemotherapy would be a boon for patients.

While the expansion of therapeutic opportunity in multiple myeloma has been incremental in some ways, it’s been continuous and, when seen in aggregate, the impact is considerable.

It may be difficult for many who have not lived through an outbreak to appreciate how critical it is to never permit the disease to reappear.